Implementation of an active case management network to identify HIV‐positive infants and accelerate the initiation of antiretroviral therapy, Thailand 2015 to 2018

Abstract

Introduction Early initiation of antiretroviral therapy (ART) can reduce HIV‐related morbidity and mortality in HIV‐positive infants. We implemented an Active Case Management Network to promote early ART initiation Aiming for Cure (ACC) in August 2014. We describe ACC implementation, early infant diagnosis (EID) coverage and ART initiation during August 2014 to July 2018 compared with a national EID survey during October 2007 to September 2011 (pre‐ACC). Methods Thailand's 2014 HIV Treatment Guidelines recommend that HIV‐exposed infants have HIV polymerase chain reaction (PCR) testing at birth, one month and at two to four months. Testing is done at 14 national HIV PCR laboratories. When an HIV‐positive infant (HIV PCR+) is identified, PCR laboratory staff send the result to the hospital staff responsible for the infant's care and to the national laboratory case manager (CM). As part of ACC, the national laboratory CM alerts a regional CM who contacts the hospital staff caring for the infant to offer technical support with ART initiation and ART adherence. CMs enter clinical, demographic and laboratory data into the national ACC database. We analysed the ACC data from August 2014 to July 2018 to assess the ACC's impact on EID coverage, ART initiation and time‐to‐ART initiation. Results The uptake of EID increased from 64% (pre‐ACC) to >95% in 2018 (ACC). The number of HIV‐positive infants born declined from 429 cases (pre‐ACC) to 267 cases (ACC). Median age at the first‐positive PCR declined from 75 days (pre‐ACC) to 60 days (ACC); P < 0.001. Among 429 infants diagnosed before ACC was started, 241 (56%) received ART; during ACC, 235 (88%) of 267 HIV‐positive infants received ART. The median age at ART initiation declined from 282 days before ACC to 83 days during ACC (P < 0.001) and the median time from blood collection to ART initiation declined from 168 days before ACC to 23 days during ACC (P < 0.001). Conclusions An innovative case management network (ACC) has been established in Thailand and results suggest that the network is promoting EID and early ART initiation. The ACC model, using case‐managed PCR notification and follow‐up, may speed ART initiation in other settings.

The Effect of Routine Management Combined with Case Management Model on Social Support, Self-Efficacy, Self-Management Ability, and Psychological Flexibility of AIDS Patients

“…Compared with the conventional management mode, case management is patient-centered, and the medical institution and the patient jointly manage the disease. It has the characteristics of humanization, individualization, and strong pertinence [ 5 ]. By constantly understanding the actual needs of patients and their families, working with patients to formulate personalized medical service plans, real-time tracking, and monitoring of patients' treatment conditions will help to achieve overall and continuous care for patients and can effectively compensate insufficiency of the conventional management model [ 6 ].…”

Reaching the Hard to Reach in Thailand: Eliminating Mother-To-Child HIV Transmission

“…The Active Case Management Network initiates ART early-and thus more effectively-with the identification, categorization, and tracking of HIV-positive infants and those who are high-risk. 16…”

Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration

“…For example, in Thailand, researchers studying the HIV reservoirs and public health officers collaborated as part of the Active Case Management Network to increase the numbers of infants on ART and lower the age at ART initiation. 48 Measures are being taken to strengthen EID programs and point of care virologic testing is gaining momentum, 10 , 49 – 51 and applications now extend to monitoring of pediatric and adult HIV treatment. 52 , 53 Over the past several years, new efforts have been made to find safe and potent ARVs with appropriate formulations and dosing for neonates and young infants 54 , 55 ( clinicaltrials.gov NCT01828073; NCT 02778204).…”